New PMTCT guidelines for South Africa
2nd International Workshop on HIV & Women, 9-10 January 2012, Bethesda, USA 1 February 2012
Similar efficacy and a few gender related differences in side effects with rilpivirine vs efavirenz at 96-weeks 1 February 2012
Volume 13 Number 1/2 January/February 2012 1 February 2012
Supplement: HIV testing and risks of sexual transmission 1 February 2012
RSS Atom • ISSN 1472-4683 • Subscribe • About
On 26 February, the FDA approved a 600mg tablet formulation of the protease inhibitor darunavir (Prezista). Tibotoc, manufacturers of this drug, say that they expect the new formulation to be widely available in the US from May 2008, requiring fewer daily pills than the current 300mg formulation.
Source: FDA list serve/Tibotec PR
Links to external websites are current at time of posting but not maintained.
HIV i-Base
Treatment phoneline: 0808 800 6013 • Mon-Wed 12-4pm • Office: 020 7407 8488 • Email: admin@i-base.org.uk • Website: www.i-base.info